EBMT 2024 | Manipulating the gut microbiome to improve outcomes of alloSCT for hematological malignancies

Florent Malard, MD, PhD, Saint-Antoine Hospital and Sorbonne University, Paris, France, discusses the link between the gut microbiome (GM) and outcomes of patients undergoing allogeneic stem cell transplantation (alloSCT). Studies have determined that a decreased GM biodiversity at baseline and at neutrophil recovery is associated with lower overall survival (OS). Additionally, GM biodiversity is a predictor of clinical outcomes, graft-versus-host disease (GvHD), infectious complications, and disease relapse across several hematological malignancies. Dr Malard outlines some approaches being studied to increase GM diversity in patients, including antibiotic-sparing strategies, prebiotics (e.g., resistant potato starch), and fecal microbiota transplantation. This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.